January 9, 2023
Via: PharmaphorumThe agreement values Boston-based Albireo at $952 million, with shareholders in the company also in line for another $10-per-share payout in a contingent value right (CVR) if Bylvay (odevixibat) gets approved for a follow-up indication. Albireo secured approval in the […]
July 19, 2024
July 11, 2024
July 11, 2024